188 related articles for article (PubMed ID: 19747563)
1. JAK3: a two-faced player in hematological disorders.
Cornejo MG; Boggon TJ; Mercher T
Int J Biochem Cell Biol; 2009 Dec; 41(12):2376-9. PubMed ID: 19747563
[TBL] [Abstract][Full Text] [Related]
2. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
3. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
4. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.
Rivera-Munoz P; Laurent AP; Siret A; Lopez CK; Ignacimouttou C; Cornejo MG; Bawa O; Rameau P; Bernard OA; Dessen P; Gilliland GD; Mercher T; Malinge S
Blood Adv; 2018 Jul; 2(13):1616-1627. PubMed ID: 29986854
[TBL] [Abstract][Full Text] [Related]
5. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
6. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
7. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
8. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract][Full Text] [Related]
9. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
Zhang LL; Pan HX; Wang YX; Guo T; Liu L
Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
[TBL] [Abstract][Full Text] [Related]
10. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
Uckun FM; Pitt J; Qazi S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
[TBL] [Abstract][Full Text] [Related]
11. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice.
Suzuki K; Nakajima H; Saito Y; Saito T; Leonard WJ; Iwamoto I
Int Immunol; 2000 Feb; 12(2):123-32. PubMed ID: 10653847
[TBL] [Abstract][Full Text] [Related]
13. Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.
Li J; Nara H; Rahman M; Juliana FM; Araki A; Asao H
Cytokine; 2010 Feb; 49(2):221-8. PubMed ID: 19889552
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
Moore CA; Iasella CJ; Venkataramanan R; Lakkis FG; Smith RB; McDyer JF; Zeevi A; Ensor CR
Hum Immunol; 2017 Feb; 78(2):64-71. PubMed ID: 27998802
[TBL] [Abstract][Full Text] [Related]
15. IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo.
Recher M; Berglund LJ; Avery DT; Cowan MJ; Gennery AR; Smart J; Peake J; Wong M; Pai SY; Baxi S; Walter JE; Palendira U; Tangye GA; Rice M; Brothers S; Al-Herz W; Oettgen H; Eibel H; Puck JM; Cattaneo F; Ziegler JB; Giliani S; Tangye SG; Notarangelo LD
Blood; 2011 Dec; 118(26):6824-35. PubMed ID: 22039266
[TBL] [Abstract][Full Text] [Related]
16. A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.
Hanna DM; Fellowes A; Vedururu R; Mechinaud F; Hansford JR
Haematologica; 2014 Sep; 99(9):e156-8. PubMed ID: 24837469
[No Abstract] [Full Text] [Related]
17. Human lymphoid development in the absence of common γ-chain receptor signaling.
Kohn LA; Seet CS; Scholes J; Codrea F; Chan R; Zaidi-Merchant S; Zhu Y; De Oliveira S; Kapoor N; Shah A; Abdel-Azim H; Kohn DB; Crooks GM
J Immunol; 2014 Jun; 192(11):5050-8. PubMed ID: 24771849
[TBL] [Abstract][Full Text] [Related]
18. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
De Vita S; Mulligan C; McElwaine S; Dagna-Bricarelli F; Spinelli M; Basso G; Nizetic D; Groet J
Br J Haematol; 2007 May; 137(4):337-41. PubMed ID: 17456055
[TBL] [Abstract][Full Text] [Related]
19. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
20. Jak3 deficiency blocks innate lymphoid cell development.
Robinette ML; Cella M; Telliez JB; Ulland TK; Barrow AD; Capuder K; Gilfillan S; Lin LL; Notarangelo LD; Colonna M
Mucosal Immunol; 2018 Jan; 11(1):50-60. PubMed ID: 28513593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
